At a glance

ClinicalIndex Comparison Record

N/ACompleted· 317 enrolled

Drug / intervention

Abraxane +1 moredrug

Likely dose

Gemcitabine 1000mgfrom record

Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02555813

NCT02555813N/ACompleted

Compare CT.gov

Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients

Celgene·observational·Posted Sep 22, 2015·Updated Oct 19, 2020

In Brief

An observational study evaluating Abraxane and Gemcitabine for Metastatic Pancreatic Cancer. Completed, enrolled 317 participants across 19 sites.

Detailed Summary

This observational program collects data on tolerability, safety and efficacy regarding the use of Abraxane in metastatic pancreatic cancer patients in the daily clinical routine. Additionally data on dosage that is actually used in these patients will be collected. Patients who have pancreatic cancer and additional diseases can be documented in this study, too. Collected data might generate learnings on the optimal use of Abraxane in the daily routine setting.

Study Details

Study Typeobservational

Allocation--

Masking--

Primary Purpose--

ConditionsMetastatic Pancreatic Cancer

CountriesAustria

Collaborators--

Timeline

N/ACompletedFinished

20162017201820192020202120222023202420252026

Enrollment StartMay 2015

First PostedSep 2015

Primary CompletionSep 2020

TodayJul 2026

First PostedSep 22, 2015

Enrollment StartMay 8, 2015

Primary CompletionSep 7, 2020

TodayJul 2, 2026

Enrollment to primary: 5.3 yearsPosted 10.8 years ago

Interventions

Abraxanedrug

Abraxane By IV infusion on Days 1, 8, 15 and 28 until progression or toxicity

Gemcitabinedrug

Gemcitabine 1000mg IV infusion on Days 1, 8, 15 and 28 until disease progression or toxicity